Jefferies Financial Group Inc. Invests $4.87 Million in Immunocore Holdings plc (NASDAQ:IMCR)

Jefferies Financial Group Inc. acquired a new stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 165,000 shares of the company's stock, valued at approximately $4,868,000. Jefferies Financial Group Inc. owned about 0.33% of Immunocore at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. T. Rowe Price Investment Management Inc. grew its position in Immunocore by 3.1% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 6,700,208 shares of the company's stock worth $197,657,000 after acquiring an additional 200,373 shares during the last quarter. Primecap Management Co. CA grew its position in Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock worth $78,722,000 after acquiring an additional 196,530 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Immunocore by 1.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock worth $64,533,000 after acquiring an additional 29,832 shares during the last quarter. Tang Capital Management LLC grew its position in Immunocore by 40.7% during the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock worth $45,890,000 after acquiring an additional 450,000 shares during the last quarter. Finally, Groupama Asset Managment bought a new position in Immunocore during the 4th quarter worth approximately $17,700,000. 84.50% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the purchase, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 10.40% of the stock is owned by company insiders.

Immunocore Stock Down 1.7%

NASDAQ:IMCR traded down $0.55 during trading hours on Wednesday, reaching $31.49. 1,052,994 shares of the company traded hands, compared to its average volume of 390,459. The business's 50-day moving average price is $29.12 and its two-hundred day moving average price is $29.98. The stock has a market capitalization of $1.58 billion, a P/E ratio of -33.15 and a beta of 0.75. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $49.05. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm's quarterly revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.49) earnings per share. Analysts predict that Immunocore Holdings plc will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Morgan Stanley restated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a research report on Friday, March 7th. Mizuho dropped their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Oppenheimer increased their price objective on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 price objective on shares of Immunocore in a report on Thursday, April 10th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Immunocore in a report on Tuesday. They issued a "buy" rating and a $65.00 price objective for the company. One analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $58.89.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.